Revolution Medicines, Inc. research snapshot
RVMD AI stock analysis currently reads Revolution Medicines as a late-stage precision-oncology company whose clinical evidence improved materially after daraxonrasib showed a 13.2-month median overall survival versus 6.7 months for chemotherapy in the Phase 3 RASolute 302 trial. At the July 11, 2026 cutoff, RVMD closed near $191.13 with a verified market capitalization of $40.63 billion. The clinical result and a well-funded balance sheet support the long thesis, but the company remains pre-commercial, loss-making, diluted by its April financing, and dependent on regulatory, launch, pricing, and pipeline execution. This page is informational only and not investment advice.
Current price
$191.13
Market cap
$40.63 billion
AI score
62 / 100
Rating
Clinically de-risked oncology platform with high valuation and execution risk
Trend status
Strong uptrend, overbought and close to resistance
Data cutoff (updated weekly)
July 11, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | RVMD develops targeted RAS(ON) inhibitors for RAS-addicted cancers, with daraxonrasib as the lead potential commercial asset and several follow-on programs in clinical development. | Medium-high |
| Moat | The moat rests on differentiated RAS(ON) science, clinical data, patents, know-how, and a broad pipeline, but it will need regulatory approval, manufacturing scale, physician adoption, and durable outcomes to become an economic moat. | Medium |
| Management | CEO and chairman Mark A. Goldsmith leads a team that advanced several RAS programs and raised capital ahead of commercialization, but investors still need evidence of disciplined launch and cash allocation. | Medium-high |
| Financial trend | RVMD remains pre-commercial. FY2025 net loss was $1.131 billion, Q1 2026 net loss was $453.8 million, and 2026 GAAP operating-expense guidance was $1.7 billion to $1.8 billion. | High |
| Valuation | At $191.13, verified math shows negative PE and negative free-cash-flow yield, while price-to-book is about 25.5x. Conventional earnings multiples do not yet value the business reliably. | High |
| Technical trend | RVMD was above the 50-day and 200-day moving averages, but RSI was near 72 to 87 in public snapshots and price sat close to accumulated-volume resistance near $192.62. | Medium |
| Risk level | Risk is high. Approval, label, safety, launch, price, reimbursement, competitor, manufacturing, cash-burn, convertible-debt, and dilution risks can all change the valuation quickly. | High |
| AI confidence | Reported facts are well documented, but an AI model cannot resolve the future commercial value of an investigational oncology medicine. | High data confidence |
| Investment certainty | Clinical certainty improved after RASolute 302, while investment certainty remains lower because the current share price reflects a large portion of a successful launch narrative. | Medium-low |
RVMD AI stock forecast
The RVMD AI stock forecast uses scenario ranges rather than a point prediction. The required PE-based three-scenario tool run is not economically meaningful with negative EPS, so these ranges frame clinical, regulatory, commercial, financing, and market conditions rather than an asserted intrinsic value.
$210 to $250
More likely if daraxonrasib receives a favorable regulatory decision and launch path, the initial label supports broad adoption, follow-on Phase 3 programs add value, and commercial execution validates premium revenue assumptions without another major dilution event.
$160 to $200
More likely if regulatory progress remains on track but investors wait for launch, pricing, reimbursement, and real-world uptake evidence while operating losses and share count continue to rise.
$95 to $130
More likely if approval timing, label, safety, manufacturing, payer access, commercial uptake, a follow-on trial, or risk appetite disappoints relative to the expectations embedded in the current market value.
RVMD AI technical analysis
RVMD AI technical analysis uses the July 9, 2026 close of $191.13. This static page does not fetch request-time market data. The medium-term trend was positive, but the stock was close to resistance, overbought in public snapshots, and capable of high-volatility moves around regulatory and clinical events.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $191.13 | Closing price used for this static page around the July 11, 2026 data cutoff. |
| Near resistance | $192.62 | Accumulated-volume resistance cited in the July 9 technical snapshot. |
| Fibonacci resistance | $193.06 to $195.56 | Short-term resistance band in the same July 9 technical snapshot. |
| Near support | $189.34 to $189.98 | Short-term moving-average and Fibonacci support references. |
| Volume support | $182.08 | Nearest accumulated-volume support below the latest close. |
| 50-day moving average | $157.68 | Public statistics snapshot around July 9, 2026. Price was above this average. |
| 200-day moving average | $103.57 | Public statistics snapshot around July 9, 2026. Price was above this average. |
| Momentum | Positive but overbought | Public RSI readings were near 72 to 87, which raises pullback risk even in a strong trend. |
| Volume | Confirm breakout volume | The technical snapshot noted lower volume on a positive day, an early warning that should be checked on a live chart. |
| Volatility | High, 2.92% weekly average daily move | Clinical, regulatory, and financing news can produce gaps beyond normal technical levels. |
| Invalidation | Sustained close below $182 | A break of accumulated-volume support would weaken a short-term continuation setup. |
RVMD AI trading strategy
The RVMD AI trading strategy is a rules-based research framework, not a personalized instruction. It links price action to regulatory filings, safety updates, commercialization milestones, quarterly cash burn, share count, and upcoming clinical readouts.
Wait for RVMD to clear $192.62 to $195.56 with volume confirmation and check that there is no new regulatory, trial, financing, or competitive information changing the thesis.
Define risk before entry. A failed breakout or sustained close below $182 can serve as a rules-based invalidation condition rather than a reason to average down automatically.
If RVMD pulls back toward $182 without a deterioration in regulatory, safety, or launch evidence, review price stabilization alongside cash runway, share count, and the next material company update.
Do not treat a lower price as proof of value. Reassess the setup if the pullback follows new clinical, approval, financing, or market-access information.
Track regulatory submission and review milestones, label language, safety data, launch preparation, payer access, product revenue, operating expense, cash and marketable securities, convertible debt, share count, and pipeline readouts.
Refresh the scenario ranges after every material clinical, regulatory, earnings, or financing update. Pre-commercial valuation can change faster than a mature-company multiple.
Investment research summary
Revolution Medicines seeks to create medicines for RAS-addicted cancers. Future customers would pay if its therapies produce clinically meaningful outcomes that physicians can use, regulators approve, and health systems reimburse.
Its potential moat is RAS(ON) chemistry, clinical evidence, patents, development know-how, and a pipeline spanning several RAS variants. This moat is promising but not fully proven economically before approval and launch.
The thesis can fail if approval is delayed or narrower than expected, safety limits uptake, manufacturing or reimbursement constrains access, competitors advance, sales ramp slowly, cash burn forces more dilution, or later trials disappoint.
Management has developed multiple RAS(ON) programs, expanded commercial capabilities, and raised capital before potential launch. The next test is converting scientific progress into a disciplined regulatory and commercial organization.
Precision oncology is a durable medical need, and RAS mutations affect several large cancer populations. The opportunity is real, but oncology markets require proof across efficacy, safety, label, sequencing, payer access, and physician behavior.
The verified $40.63 billion market capitalization prices in substantial future commercial success. With negative earnings and free cash flow, margin of safety depends on clinical durability, approval, launch execution, and future financing rather than a mature earnings multiple.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| RVMD price | $191.13 at the July 9, 2026 close | StockAnalysis quote and StockInvest technical snapshot | July 11, 2026 |
| Market capitalization | $40.63 billion, verified with financial_rigor.py using $191.13 and 212.60 million shares at 0.00% variance | StockInvest quote snapshot and StockAnalysis statistics | July 11, 2026 |
| Shares outstanding | 212.60 million, with shares up 10.96% year over year | StockAnalysis statistics | July 11, 2026 |
| FY2025 net loss and R&D | $1.131 billion net loss and $987.3 million R&D expense, each cross-validated against third-party financial data | Revolution Medicines FY2025 results | July 11, 2026 |
| Q1 2026 cash and financing | $1.9 billion in cash, cash equivalents, and marketable securities at March 31, followed by $2.1 billion net proceeds from April concurrent financings | Revolution Medicines Q1 2026 results | July 11, 2026 |
| Q1 2026 loss and expense guidance | $453.8 million net loss and $1.7 billion to $1.8 billion full-year GAAP operating-expense guidance | Revolution Medicines Q1 2026 results | July 11, 2026 |
| RASolute 302 Phase 3 result | Median overall survival of 13.2 months with daraxonrasib versus 6.7 months with chemotherapy in the intent-to-treat population, hazard ratio 0.40 | Revolution Medicines Phase 3 release | July 11, 2026 |
| Valuation and balance sheet | Negative PE and FCF yield, about 25.5x book value, $1.91 billion cash, and $437.27 million total debt in the current third-party snapshot | StockAnalysis statistics | July 11, 2026 |
| Technical levels | Resistance near $192.62 and $193.06 to $195.56, support near $189.34 to $189.98 and $182.08, with 2.92% weekly average daily volatility | StockInvest RVMD technical snapshot | July 11, 2026 |
This RVMD page is an informational research tool, not investment advice or a recommendation to buy or sell securities. Forecast scenarios use available data and assumptions that may be wrong. Clinical, regulatory, commercial, financing, and market outcomes can change quickly, and users should verify current information and consider professional advice before making an investment decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
